JP2010502762A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502762A5
JP2010502762A5 JP2009527796A JP2009527796A JP2010502762A5 JP 2010502762 A5 JP2010502762 A5 JP 2010502762A5 JP 2009527796 A JP2009527796 A JP 2009527796A JP 2009527796 A JP2009527796 A JP 2009527796A JP 2010502762 A5 JP2010502762 A5 JP 2010502762A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
modified release
release pharmaceutical
inhibitor
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009527796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502762A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/059443 external-priority patent/WO2008031782A1/en
Publication of JP2010502762A publication Critical patent/JP2010502762A/ja
Publication of JP2010502762A5 publication Critical patent/JP2010502762A5/ja
Withdrawn legal-status Critical Current

Links

JP2009527796A 2006-09-12 2007-09-10 ファクターXa阻害剤を含有する複数のミニ錠剤を含む、医薬組成物 Withdrawn JP2010502762A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12
PCT/EP2007/059443 WO2008031782A1 (en) 2006-09-12 2007-09-10 Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor

Publications (2)

Publication Number Publication Date
JP2010502762A JP2010502762A (ja) 2010-01-28
JP2010502762A5 true JP2010502762A5 (enExample) 2010-10-28

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527796A Withdrawn JP2010502762A (ja) 2006-09-12 2007-09-10 ファクターXa阻害剤を含有する複数のミニ錠剤を含む、医薬組成物

Country Status (16)

Country Link
US (1) US20090285887A1 (enExample)
EP (1) EP2061439A1 (enExample)
JP (1) JP2010502762A (enExample)
KR (1) KR20090052346A (enExample)
CN (1) CN101516355A (enExample)
AR (1) AR062721A1 (enExample)
AU (1) AU2007296311A1 (enExample)
BR (1) BRPI0716234A2 (enExample)
CA (1) CA2662542A1 (enExample)
CL (1) CL2007002618A1 (enExample)
EA (1) EA200970267A1 (enExample)
IL (1) IL197295A0 (enExample)
MX (1) MX2009002669A (enExample)
PE (1) PE20080661A1 (enExample)
TW (1) TW200824723A (enExample)
WO (1) WO2008031782A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
SI3246021T1 (sl) * 2010-02-25 2020-03-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
RU2013113627A (ru) * 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
MX370873B (es) 2010-10-15 2020-01-08 Brain Sentinel Inc Metodo y aparato para detectar convulsiones.
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
WO2014033077A1 (en) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
US20190046449A1 (en) * 2016-02-25 2019-02-14 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Similar Documents

Publication Publication Date Title
JP2010502762A5 (enExample)
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
US10555907B2 (en) Controlled-release solid dosage forms of mesalamine
CN102869349A (zh) 耐酒精的肠溶药物组合物
JP2009538920A5 (enExample)
CN103096881A (zh) 含有具有不愉快味道的药物的膜制剂
CN103118666A (zh) 含有利福昔明的药物制剂、制备其的方法和治疗肠疾病的方法
AU2007254215A1 (en) Methods and compositions for the treatment of viral infections
CN104114163A (zh) 治疗心血管疾病的方法
US20210145804A1 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
CN115581696A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
EP1462098B1 (en) Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
US12239660B2 (en) Therapeutic composition and methods
US20140066516A1 (en) Novel Method
JP2004536829A5 (enExample)
WO2021163007A1 (en) Therapeutic composition and methods
JP2024507367A (ja) ムスカリン受容体活性化によって改善される障害を処置するための方法
KR20190092805A (ko) 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
CN102056602A (zh) 决奈达隆用于预防心脏复律
WO2021101875A1 (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
CN1173698C (zh) 包含包衣的雷尼替丁、碱式柠檬酸铋和硫糖铝的对胃肠障碍具有治疗作用的可口服给药的药物制剂
CN117136048A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的方法
IT201800005908A1 (it) Compressa gastroresistente rivestita con film per il rilascio protratto di acido butirrico
AU2016344673A1 (en) Pharmaceutical compositions of dimethyl fumarate
JP2008520607A5 (enExample)